Please select the option that best describes you:
Do you offer memantine for cognitive preservation to glioma patients?
In particular, would you offer memantine to those with WHO II or III gliomas and a good performance status but larger treatment volume?
Answer from: Radiation Oncologist at Academic Institution
I do not as there is currently no evidence to support this. There was a trial conducted by the RTOG for whole brain RT patients with mets which demonstrated a trend towards improvement in time to cognitive decline (53.8 % at 24 weeks for memantine vs 64.9 % for placebo), executive function at 8 and ...
Sign In or Register to read more